Targeting IL-1 controls refractory pityriasis rubra pilaris
Eloi Schmauch1,2,3, Yannik Severin4, Xianying Xing5
1Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Science Advances
|July 3, 2024
Summary
Pityriasis rubra pilaris (PRP) is driven by Interleukin-1 beta (IL-1β). Targeting IL-1β with specific antagonists rapidly improved patient skin lesions and reversed disease markers, suggesting a new classification for this rare inflammatory skin condition.
Area of Science:
- Dermatology
- Immunology
- Genetics
Background:
- Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder with unclear causes.
- Understanding the molecular mechanisms of PRP is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the underlying molecular pathways in Pityriasis rubra pilaris (PRP).
- To identify key mediators and potential therapeutic targets for PRP.
Main Methods:
- Molecular pathway analysis of skin samples from PRP patients, psoriasis, atopic dermatitis, healed PRP, and healthy controls.
- Investigated the role of Interleukin-1 beta (IL-1β) and associated signaling pathways (NF-κB, CARD14, NOD2).
- Treated three PRP patients with IL-1β antagonists (anakinra, canakinumab) and analyzed clinical and molecular responses.
Main Results:
- Identified IL-1β as a central mediator in PRP, driving an NF-κB-mediated IL-1β-CCL20 axis.
- IL-1β stimulation of keratinocytes in vitro mirrored the transcriptional signature observed in PRP.
- Treatment with IL-1β antagonists led to rapid clinical improvement (50% lesion reduction in 2-3 weeks) and reversal of molecular markers.
Conclusions:
- IL-1β is a key therapeutic target for Pityriasis rubra pilaris (PRP).
- Findings support redefining PRP as an autoinflammatory keratinization disorder.
- Further clinical trials are warranted to confirm the efficacy of IL-1β antagonists in PRP treatment.
